Exercise Therapy for Asthma (ETA Trial)

NCT ID: NCT00839137

Last Updated: 2021-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

13 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-12-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine if a program of regular exercise can help reduce asthma symptoms and also reduce the inflammation caused by asthma. If successful, this would allow regular exercise to be recommended as a therapy for people with asthma, which could possibly reduce the amount of medicine that people with asthma need to control their asthma symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, controlled, parallel-design study of the effectiveness of exercise therapy as add-on therapy in the treatment of mild to moderately severe asthma.

105 men and women between the ages of 18-50 years with asthma will be randomly assigned to one of two treatment groups: exercise therapy or control. The exercise therapy protocol is detailed below. The control group will receive usual asthma care. The control group will be instructed to maintain their current sedentary activity level, i.e. not to begin a formal or informal exercise program. In order to standardize contact with study personnel between the two groups the control group will be seen three times a week for clinic visits (exercise group will have sessions three times a week). The primary outcome measures are asthma control (asthma symptom score) and asthma-related inflammation. Secondary outcomes include exacerbation rate, asthma-related quality of life, generic quality of life, lung function, airways hyper-reactivity, and cardiovascular fitness. The effect of exercise therapy on inflammatory markers in blood, and sputum will be assessed by comparing results obtained at study completion versus those obtained at baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

asthma exercise therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no exercise program group

group will continue with current level of activity and will be asked not to start an exercise program. They will be seen in the clinic three times a week for 12 weeks. These visits will be very brief; blood pressure, heart rate, oxygen level and peak flow will be measured at each visit

No interventions assigned to this group

exercise group

will meet three times a week for 12 weeks, following specific exercise program

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • 18-50 years old

* 50 + years old with prior approval to begin an exercise program from primary care physician within 6 months of enrollment
* Men and women

Asthma:

* Doctor diagnosed asthma
* Lung function tests must meet certain levels common in asthma patients
* Active, daily doctor-prescribed asthma controller medication (inhaled corticosteroid) for 2 months or longer at a minimum dose equivalent to fluticasone 88 mcg/day, about two (2) puffs. (you can be on other drugs as long as they are in the same dose range as fluticasone)
* Poor asthma control: Any one of the following conditions:

* Use of beta-agonist (A bronchodilator medicine that opens the airways by relaxing the muscles around the airways that may tighten during an asthma attack )for asthma symptoms twice/week or more OR
* Awakening from sleep with asthma symptoms more than once per week OR
* One or more control problems identified on the Asthma Treatment and Control Questionnaire (ATAQ).

Smoking status:

* Non-smoker for 6 months or longer
* Less than 10 pack year (number of packs per day (x) years of smoking = pack years) smoking history

Exclusion Criteria

* • Poor lung function

* Current participation in a regular aerobic exercise program (formal or at home)
* Any "yes" to any one of items a-e of question number two of the Stanford Usual Activity Questionnaire
* Pregnancy
* Sudden illness that accompanies fever (\> 38.00 C or 100.40F) within 24 hours of Visit 2
* Participation in another interventional research trial Other major chronic illnesses that would interfere with participation in the study

Medication use:

* Chronic oral corticosteroid use
* Oral corticosteroid use within 4 weeks of study start
* Anti-coagulants (An anticoagulant is a drug that helps prevent the clotting (coagulation) of blood.), insulin, any investigative drugs within 2 months

Drug allergy:

• Previous adverse effects from methacholine challenge

Non-adherence:

* Inability or unwillingness to provide consent
* Inability to perform aerobic exercise
* Inability to perform baseline measurements
* Less than 80% completion of screening period diaries
* Inability to contact by telephone
* Intention to move out of the area within 6 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ohio State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John G Mastronarde, MD

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Ohio State University

Columbus, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2003H0213

Identifier Type: -

Identifier Source: org_study_id